Immuno-Biological Laboratories plans pilot-plant for recombinant products expressed in silkworms

The pilot-plant will be built in Maebashi, Gunma Prefecture, and allow for the production under GMP regulations. At present, IBL does joint research with Astellas Pharma for the production of human fibrinogen from the silkworm cocoon and studies the expression of recombinant antibodies and enzymes in this organism.

IBL news release, Dec. 19, 2014

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny